Kodiak Sciences Inc.

NASDAQ (USD): Kodiak Sciences Inc. (KOD)

Last Price

2.61

Today's Change

+0.10 (3.98%)

Day's Change

2.36 - 2.61

Trading Volume

199,892

Overview

Market Cap

137 Million

Shares Outstanding

52 Million

Avg Volume

241,412

Avg Price (50 Days)

2.69

Avg Price (200 Days)

3.60

PE Ratio

-0.69

EPS

-3.77

Earnings Announcement

12-Nov-2024

Previous Close

2.51

Open

2.54

Day's Range

2.36 - 2.61

Year Range

1.37 - 7.77

Trading Volume

199,892

Price Change Highlight

1 Day Change

3.98%

5 Day Change

-6.45%

1 Month Change

-9.06%

3 Month Change

-4.40%

6 Month Change

-58.24%

Ytd Change

-17.92%

1 Year Change

27.94%

3 Year Change

-97.44%

5 Year Change

-83.53%

10 Year Change

-74.31%

Max Change

-74.31%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment